Fernanda Tavares

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. doi request reprint Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective
    Fernanda Tavares
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Vaccine 29:6402-7. 2011
  2. doi request reprint Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study
    Fernanda Tavares
    Global Vaccine Development, GlaxoSmithKline GSK Biologicals, Parc de la Noire Epine, Avenue Fleming 20, 1300 Wavre, Belgium
    Vaccine 29:6358-65. 2011
  3. doi request reprint The safety evaluation of adjuvants during vaccine development: the AS04 experience
    Nathalie Garçon
    GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium
    Vaccine 29:4453-9. 2011

Collaborators

  • Nathalie Garçon
  • Lawrence Segal
  • Marcelle Van Mechelen

Detail Information

Publications3

  1. doi request reprint Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective
    Fernanda Tavares
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Vaccine 29:6402-7. 2011
    ..Our analysis also highlighted the challenges of reliably determining the rate of anaphylaxis as an adverse event in the postmarketing setting following mass vaccination, as anaphylaxis was excluded in 45.8% of reported cases...
  2. doi request reprint Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study
    Fernanda Tavares
    Global Vaccine Development, GlaxoSmithKline GSK Biologicals, Parc de la Noire Epine, Avenue Fleming 20, 1300 Wavre, Belgium
    Vaccine 29:6358-65. 2011
    ....
  3. doi request reprint The safety evaluation of adjuvants during vaccine development: the AS04 experience
    Nathalie Garçon
    GlaxoSmithKline Biologicals, Avenue Fleming, 20, 1300 Wavre, Belgium
    Vaccine 29:4453-9. 2011
    ..We also discuss how the knowledge of adjuvant mode of action can support the current practice of safety evaluation...